Recent Advances in Nanoenzymes Based Therapies for Glioblastoma: Overcoming Barriers and Enhancing Targeted Treatment
Source abstract
Abstract
Abstract Glioblastoma multiforme (GBM) is a highly aggressive and malignant brain tumor originating from glial cells, characterized by high recurrence rates and poor patient prognosis. The heterogeneity and complex biology of GBM, coupled with the protective nature of the blood–brain barrier (BBB), significantly limit the efficacy of traditional therapies. The rapid development of nanoenzyme technology presents a promising therapeutic paradigm for the rational and targeted treatment of GBM. In this review, the underlying mechanisms of GBM pathogenesis are comprehensively discussed, emphasizing the impact of the BBB on treatment strategies. Recent advances in nanoenzyme‐based approaches for GBM therapy are explored, highlighting how these nanoenzymes enhance various treatment modalities through their multifunctional capabilities and potential for precise drug delivery. Finally, the challenges and therapeutic prospects of translating nanoenzymes from laboratory research to clinical application, including issues of stability, targeting efficiency, safety, and regulatory hurdles are critically analyzed. By providing a thorough understanding of both the opportunities and obstacles associated with nanoenzyme‐based therapies, future research directions are aimed to be informed and contribute to the development of more effective treatments for GBM.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Shengjing Hospital of China Medical University Liaoning 110004 China
Shenyang Sport University Liaoning 110102 China
Institute of Systems Biomedicine Beijing Key Laboratory of Tumor Systems Biology School of Basic Medical Sciences Peking University Beijing 100191 China
The First Hospital of China Medical University Liaoning 110001 China
Funding
Clinical Trial Center, China Medical University Hospital
References (100+)
Show source-provided references
1. 10.1038/s41582-018-0025-810.1038/s41582-018-0025-8 ↗
2. 10.1038/s41571-018-0003-510.1038/s41571-018-0003-5 ↗
3. 10.3322/caac.2161310.3322/caac.21613 ↗
4. 10.1124/pr.117.01494410.1124/pr.117.014944 ↗
5. 10.1016/j.addr.2021.01.01210.1016/j.addr.2021.01.012 ↗
6. 10.1016/j.ctrv.2019.10189610.1016/j.ctrv.2019.101896 ↗
7. 10.1038/s41582-022-00621-010.1038/s41582-022-00621-0 ↗
8. 10.1001/jama.2023.002310.1001/jama.2023.0023 ↗
9. 10.1038/s41416-018-0258-810.1038/s41416-018-0258-8 ↗
10. 10.1016/j.trecan.2022.09.00510.1016/j.trecan.2022.09.005 ↗
11. 10.1038/s41590-019-0433-y10.1038/s41590-019-0433-y ↗
12. Lukas R. V. · Oncology · 2019 · 33 · 91
13. 10.1016/j.cub.2020.06.08110.1016/j.cub.2020.06.081 ↗
14. 10.1242/jcs.11639210.1242/jcs.116392 ↗
15. Sweeney M. D. · Physiol. Rev. · 2018
16. 10.1101/cshperspect.a02041210.1101/cshperspect.a020412 ↗
17. 10.1038/s41568-019-0205-x10.1038/s41568-019-0205-x ↗
18. 10.1038/s41573-021-00139-y10.1038/s41573-021-00139-y ↗
19. 10.1002/adma.20240244510.1002/adma.202402445 ↗
20. 10.1016/j.jconrel.2023.05.00910.1016/j.jconrel.2023.05.009 ↗
21. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
22. 10.1016/S2215-0366(17)30293-610.1016/S2215-0366(17)30293-6 ↗
23. 10.1016/j.canlet.2016.01.04310.1016/j.canlet.2016.01.043 ↗
24. 10.1126/sciadv.abc703110.1126/sciadv.abc7031 ↗
25. 10.1073/pnas.191201211710.1073/pnas.1912012117 ↗
26. 10.1016/j.jconrel.2020.07.00710.1016/j.jconrel.2020.07.007 ↗
27. 10.1016/j.nantod.2019.02.00510.1016/j.nantod.2019.02.005 ↗
28. 10.1038/s41392-023-01536-y10.1038/s41392-023-01536-y ↗
29. 10.1016/j.biomaterials.2024.12285210.1016/j.biomaterials.2024.122852 ↗
30. 10.1016/j.jconrel.2024.02.03910.1016/j.jconrel.2024.02.039 ↗
31. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
32. 10.1038/s41568-022-00496-910.1038/s41568-022-00496-9 ↗
33. 10.1021/acsnano.3c1112510.1021/acsnano.3c11125 ↗
34. 10.1039/D0CC05427E10.1039/D0CC05427E ↗
35. 10.1002/adfm.20210865010.1002/adfm.202108650 ↗
36. 10.1002/adma.20200724710.1002/adma.202007247 ↗
37. 10.1038/s41591-018-0014-x10.1038/s41591-018-0014-x ↗
38. 10.1158/2159-8290.CD-20-180810.1158/2159-8290.CD-20-1808 ↗
39. 10.1186/s12964-020-0530-410.1186/s12964-020-0530-4 ↗
40. 10.1002/med.2176510.1002/med.21765 ↗
41. 10.1038/s41588-022-01141-910.1038/s41588-022-01141-9 ↗
42. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
43. 10.1016/j.jconrel.2022.03.04310.1016/j.jconrel.2022.03.043 ↗
44. 10.1016/j.addr.2022.11461410.1016/j.addr.2022.114614 ↗
45. 10.1016/j.nantod.2020.10097010.1016/j.nantod.2020.100970 ↗
46. 10.1002/adhm.20240237610.1002/adhm.202402376 ↗
47. 10.1016/j.addr.2022.11444910.1016/j.addr.2022.114449 ↗
48. 10.1016/j.addr.2020.07.00310.1016/j.addr.2020.07.003 ↗
49. 10.1016/j.biomaterials.2019.01.02510.1016/j.biomaterials.2019.01.025 ↗
50. 10.1021/acs.molpharmaceut.2c0038310.1021/acs.molpharmaceut.2c00383 ↗
51. 10.3390/nano809063410.3390/nano8090634 ↗
52. 10.1039/D1CS00918D10.1039/D1CS00918D ↗
53. 10.1093/annonc/mdh09710.1093/annonc/mdh097 ↗
54. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
55. 10.2147/DDDT.S14611110.2147/DDDT.S146111 ↗
56. 10.1080/10428194.2019.166097010.1080/10428194.2019.1660970 ↗
57. 10.1021/acs.accounts.9b0014010.1021/acs.accounts.9b00140 ↗
58. 10.1016/j.cej.2021.12943110.1016/j.cej.2021.129431 ↗
59. 10.1016/j.ccr.2021.21417010.1016/j.ccr.2021.214170 ↗
60. 10.1016/j.addr.2016.05.02210.1016/j.addr.2016.05.022 ↗
61. 10.1016/j.jconrel.2020.06.03210.1016/j.jconrel.2020.06.032 ↗
62. 10.1002/adma.20190019210.1002/adma.201900192 ↗
63. Dougherty T. J. · 2020 · 423
64. 10.1002/adhm.20190013210.1002/adhm.201900132 ↗
65. 10.1016/j.biomaterials.2020.11982710.1016/j.biomaterials.2020.119827 ↗
66. 10.1016/j.nantod.2020.10094610.1016/j.nantod.2020.100946 ↗
67. 10.1002/anie.20221041510.1002/anie.202210415 ↗
68. 10.1002/adma.20210422310.1002/adma.202104223 ↗
69. 10.1007/s40820-021-00717-010.1007/s40820-021-00717-0 ↗
70. 10.1039/D3TB00451A10.1039/D3TB00451A ↗
71. 10.1007/s40820-022-00828-210.1007/s40820-022-00828-2 ↗
72. Grech N. · Cureus · 2020 · 12
73. 10.1016/j.amjmed.2017.12.03910.1016/j.amjmed.2017.12.039 ↗
74. 10.1007/978-981-10-9035-6_3310.1007/978-981-10-9035-6_33 ↗
75. 10.1007/s12035-020-01892-810.1007/s12035-020-01892-8 ↗
76. 10.13005/bpj/151110.13005/bpj/1511 ↗
77. Weathers S.‐P. · Oncology · 2015 · 29 · 719
78. 10.3892/or.2017.539110.3892/or.2017.5391 ↗
79. 10.1016/j.cellsig.2023.11068310.1016/j.cellsig.2023.110683 ↗
80. 10.1038/s41590-020-00860-710.1038/s41590-020-00860-7 ↗
81. 10.2147/IJN.S14046210.2147/IJN.S140462 ↗
82. 10.1038/s41588-018-0318-210.1038/s41588-018-0318-2 ↗
83. 10.1158/0008-5472.CAN-18-254510.1158/0008-5472.CAN-18-2545 ↗
84. 10.1007/s10456-023-09876-710.1007/s10456-023-09876-7 ↗
85. 10.2147/CMAR.S18614210.2147/CMAR.S186142 ↗
86. 10.1016/j.ctrv.2018.06.01710.1016/j.ctrv.2018.06.017 ↗
87. 10.7150/thno.4169210.7150/thno.41692 ↗
88. 10.1016/j.trecan.2020.01.00910.1016/j.trecan.2020.01.009 ↗
89. 10.1016/j.stem.2018.03.01110.1016/j.stem.2018.03.011 ↗
90. 10.1038/s41586-020-2612-210.1038/s41586-020-2612-2 ↗
91. 10.1038/s41392-021-00544-010.1038/s41392-021-00544-0 ↗
92. 10.15252/embj.20179877210.15252/embj.201798772 ↗
93. Singh N. · Cancer Drug Resist. · 2021 · 4 · 17
94. 10.1111/jnc.1425010.1111/jnc.14250 ↗
95. 10.1016/j.wneu.2018.04.02210.1016/j.wneu.2018.04.022 ↗
96. 10.1016/j.canlet.2018.08.00410.1016/j.canlet.2018.08.004 ↗
97. 10.1016/j.biomaterials.2018.01.05310.1016/j.biomaterials.2018.01.053 ↗
98. 10.1158/1078-0432.CCR-19-387410.1158/1078-0432.CCR-19-3874 ↗
99. 10.1002/cam4.137510.1002/cam4.1375 ↗
100. 10.15252/embj.201910379010.15252/embj.2019103790 ↗